ARTICLE | Company News
Chinook to spin AbbVie castoff into personalized kidney disease candidate
January 11, 2020 12:05 AM UTC
The trend towards personalized medicine for renal diseases continues with Chinook’s licensing of atrasentan from AbbVie. The biotech plans to put its precision medicine spin on the endothelin A receptor while transitioning it from the large diabetic nephropathy indication to a rare disease setting.
Chinook Therapeutics Inc. licensed worldwide, exclusive rights to atrasentan for all indications for an undisclosed upfront payment plus milestones and royalties. AbbVie Inc. (NYSE:ABBV) also took an equity stake in the company. ...